Welcome to our dedicated page for Proqr Therapeuti news (Ticker: PRQR), a resource for investors and traders seeking the latest updates and insights on Proqr Therapeuti stock.
ProQR Therapeutics N.V. (Nasdaq: PRQR) generates a steady flow of news as a clinical-stage biopharmaceutical company advancing RNA editing therapies. Its updates center on the Axiomer RNA base editing platform and a pipeline of editing oligonucleotides designed to correct or modulate disease-related targets at the RNA level. News coverage on this page reflects company announcements, clinical milestones, financial updates, and scientific presentations related to its programs in liver, CNS, and other genetically defined diseases.
Investors and followers of PRQR can expect news about the progress of AX-0810, ProQR’s lead investigational RNA editing oligonucleotide targeting NTCP for cholestatic diseases. Recent releases describe the submission and authorization of a Clinical Trial Application, the initiation of a Phase 1 first-in-human study in healthy volunteers in the Netherlands, and early safety and pharmacokinetic observations from the first cohort. Updates also outline plans for target engagement readouts and the future inclusion of a patient cohort in the same trial.
News items also highlight earlier-stage pipeline programs such as AX-2402 for Rett syndrome (MECP2 R270X), AX-2911 for metabolic liver disease including MASH (PNPLA3 I148M), and AX-1412 for cardiovascular disease (B4GALT1). ProQR reports non-clinical proof-of-concept data, development candidate selections, and functional results in disease-relevant models. Financial press releases provide quarterly operating and financial results, cash and cash equivalents, collaboration revenue from Eli Lilly, and comments on cash runway.
Additional PRQR news covers participation in scientific and investor conferences, including ASGCT, the RNA Editing Summit, OTS, TIDES USA, and healthcare investor events. These communications feature presentations on ADAR-mediated RNA editing of NTCP, PNPLA3, and MECP2, as well as platform-focused talks on optimizing editing oligonucleotides for therapeutic use. Bookmark this page to follow ProQR’s disclosed clinical data, pipeline milestones, collaboration developments, and financial reporting as they are released through press announcements and SEC-furnished materials.
ProQR Therapeutics (Nasdaq: PRQR) has priced an underwritten public offering of 18 million ordinary shares at $3.50 per share, raising gross proceeds of $63.0 million. The company also granted underwriters a 30-day option to purchase up to 2.7 million additional shares. Concurrently, Eli Lilly agreed to purchase 3.52 million shares in a private placement at the same price to maintain its 16.4% ownership stake, contributing additional gross proceeds of $12.3 million. The combined proceeds will fund research, development, and clinical programs, along with working capital and general corporate purposes. The offering is expected to close on October 24, 2024.
ProQR Therapeutics N.V. (Nasdaq: PRQR), a company focused on RNA therapies using its Axiomer™ RNA editing technology platform, has announced a proposed underwritten public offering of its ordinary shares. The company intends to grant underwriters a 30-day option to purchase up to an additional 15% of the offering amount. Proceeds from the offering will be used to fund research and development, clinical development, and general corporate purposes.
Joint lead bookrunning managers for the offering include Evercore ISI, Cantor, Raymond James, and Oppenheimer & Co. A shelf registration statement on Form F-3 has been filed with the SEC and declared effective. The offering is subject to market conditions, and there is no assurance of its completion or terms.
ProQR Therapeutics NV (Nasdaq: PRQR), a company focused on transformative RNA therapies using its proprietary Axiomer™ RNA editing technology platform, has announced its participation in the 2024 Cantor Global Healthcare Conference. The event is scheduled for Tuesday, September 17 at 9:10 am ET in New York City. Company management will present in a fireside chat format, which will be accessible via live webcast from the 'Investors & Media' section of ProQR's website under 'Events'. For those unable to attend live, a replay of the webcast will be available for approximately 30 days following the presentation.
ProQR Therapeutics NV (Nasdaq: PRQR) reported its Q2 2024 financial and operating results. Key highlights include:
- AX-0810 (for cholestatic diseases) and AX-1412 (for cardiovascular diseases) programs advancing to clinic in late 2024/early 2025
- $4.5 million in milestones achieved in H1 from Lilly partnership
- €96.2 million cash position as of Q2 end, providing runway into mid-2026
- Net loss of €2.7 million (€0.03 per diluted share) for Q2 2024
- R&D costs increased to €7.1 million in Q2 2024 from €5.9 million in Q2 2023
- General and administrative costs decreased to €3.0 million in Q2 2024 from €4.1 million in Q2 2023
ProQR plans to announce translational data and clinical trial designs for AX-0810 and AX-1412 in H2 2024.
ProQR Therapeutics (Nasdaq: PRQR) announced its participation in the RNA Editing Summit from June 18-20, 2024, in Boston. Gerard Platenburg, Chief Scientific Officer and Co-Founder, will present on June 20 at 2:00pm ET. The presentation, titled “Developing Axiomer RNA Editing Technology Towards Clinical Development,” will focus on ProQR’s ADAR-mediated Axiomer RNA editing technology, optimization strategies, and the AX-0810 program targeting NTCP for cholestatic diseases. The presentation will also cover in vivo models of biomarkers for NTCP and will be accessible on ProQR’s website under Presentations & Publications.
ProQR Therapeutics NV. (Nasdaq: PRQR) reported Q1 2024 financial results, highlighting preclinical data for the AX-0810 program targeting NTCP for cholestatic diseases. The company presented successful defense of its IP estate and announced Martin Maier, PhD's nomination to the Board. ProQR emphasized its strong cash position of €102.7 million providing runway into mid-2026.
ProQR Therapeutics NV announced preclinical proof of concept data for its AX-0810 Axiomer™ RNA editing program targeting NTCP for cholestatic diseases. The data, presented at the ASGCT Annual Meeting, revealed significant progress in RNA editing technology. The AX-0810 program aims to reduce bile acid concentration in the liver by targeting NTCP, representing a promising approach for cholestatic disorders. The company plans to advance the program to the clinic in late 2024/early 2025, with additional milestones expected for the Axiomer pipeline.
Summary not available.
Summary not available.
Summary not available.
FAQ
What is the current stock price of Proqr Therapeuti (PRQR)?
What is the market cap of Proqr Therapeuti (PRQR)?
